← Benitec Biopharma Inc. (BNTC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Benitec Biopharma Inc. (BNTC)
Pharmaceutical Preparations · market cap $351M · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Benitec Biopharma (BNTC) is a micro-cap clinical-stage gene therapy company with 19 employees and a single disclosed pipeline asset, BB-401, currently in Phase 2 development for Head and Neck Squamous Cell Carcinoma (HNSCC). The company has generated no revenue across at least four fiscal years and carries persistent annual net losses, most recently approximately $9M in 2025. Key financial details — cash position, runway, dilution history, and short interest — are not available in the provided data set.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BB-401 | Phase 2 | Head and Neck Squamous Cell Carcinoma |
Price & technical context
3-month
-27.5%
6-month
-12.7%
12-month
-31.7%
52-wk range
$9.58–$16.52
vs 50-day MA
-20.1%
vs 200-day MA
-19.6%
Realized vol
61.0%
Max drawdown
-42.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BNTC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.